Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval
This article was originally published in The Tan Sheet
Executive Summary
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.
You may also be interested in...
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap
A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.